By Kyle Morris

IQ-AI Ltd. said Tuesday that its Imaging Biometrics subsidiary has submitted an application to the U.S. Food and Drug Administration for its IB Zero G software.

The U.K. medical-software and services company said the software eliminates the need for gadolinium-based contrast agents in magnetic resonance imaging exams.

Shares in IQ-AI at 0729 GMT were up 0.38 pence, or 9.4%, at 4.38 pence.

Write to Kyle Morris at kyle.morris@dowjones.com

(END) Dow Jones Newswires

May 31, 2022 04:02 ET (08:02 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.
Iq-ai (LSE:IQAI)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more Iq-ai Charts.
Iq-ai (LSE:IQAI)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Iq-ai Charts.